<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221321</url>
  </required_header>
  <id_info>
    <org_study_id>IN_APA_114</org_study_id>
    <nct_id>NCT04221321</nct_id>
  </id_info>
  <brief_title>Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Multiple-dose, Replicated Crossover Study to Evaluate Drug-drug Interaction Following Co-administration of Tegoprazan or RAPA114 With Atorvastatin in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the influence of tegoprazan or RAPA114 on the Pharmacokinetic
      characteristics of atorvastatin following co-administration of tegoprazan or RAPA114 in
      healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Pharmacokinetic Assessments] : Blood concentration of atorvastatin, 2-OH atorvastatin

        -  Primary outcome: AUCτ, Css,max of atorvastatin

        -  Secondary outcome: Tss,max of atorvastatin, AUCτ, Css,max of 2-OH atorvastatin,
           metabolic ratio

      [Sefety Assessments]

      : Safety assessments with adverse event monitoring including subjective/objective symptoms,
      physical examination, vital signs, electrocardiogram, and laboratory test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ of atorvastatin</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>Area under the plasma drug concentration-time curve at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max of atorvastatin</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>Maximum concentration of drug in plasma of atorvastatin at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tss,max of atorvastatin</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>Time to Cmax at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ of 2-OH atorvastatin</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>Area under the plasma drug concentration-time curve at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,max of 2-OH atorvastatin</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>Maximum concentration of drug in plasma of 2-OH atorvastatin at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio</measure>
    <time_frame>Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period</time_frame>
    <description>AUCτ of 2-OH atorvastatin / AUCτ of atorvastatin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of Atorvastatin 40 mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg + Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg + RAPA114</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 mg</intervention_name>
    <description>Atorvastatin 40 mg</description>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg + RAPA114</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Atorvastatin 40 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAPA114</intervention_name>
    <description>RAPA114 tablet</description>
    <arm_group_label>Atorvastatin 40 mg + RAPA114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male adults aged 19 to 55 years (inclusive) at the time of his consent.

          -  Body mass index (BMI) ≥ 19.0 and ≤ 27.0 kg/m2 at screening.

          -  Decides to participate voluntarily in the trial after being fully informed of and
             understanding the study completely, and provides the written informed consent to
             participate in the trial and to comply with the trial-specific requirements.

          -  Has the ability and willingness to participate in the entire period of clinical trial.

        Exclusion Criteria:

          -  A subject with clinically significant disease or history of hepatobiliary, renal,
             gastrointestinal, cardiovascular, musculoskeletal, endocrine, respiratory,
             neuropsychiatry or hemato-oncologic system, etc.

          -  A subject with a history of hypersensitivity reactions to main constituents of or
             identical affiliation of the investigational products (ex, HMG-CoA reductase
             inhibitor, gastric acid suppressants), or have allergic diseases that require
             treatment.

          -  A subject with a history of genetic myopathy or family history.

          -  A subject who has participated in other clinical trials and received the
             investigational products within 180 days prior to the randomization.

          -  A subject who received any medications or foods that could significantly affect the
             absorption, distribution, metabolism, or excretion of an investigational product
             within 30 days prior to the randomization.

          -  A subject with history of whole blood donation within 60 days, or with blood
             components or received transfusion within 30 days prior to the randomization.

          -  A subject with continued consumption of alcohol more than 140 g per week.

          -  A subject with AST, ALT, or γ-GT levels exceeding 1.5 times of the upper limit of the
             reference range in the screening test.

          -  A subject with a calculated glomerular filtration rate of less than 60 mL / min / 1.73
             m2 in the screening test.

          -  A subject with any positive result on serology tests for hepatitis B, hepatitis C, HIV
             or syphilis in the screening test.

          -  A subject with galactose intolerance, Lapp lactose dehydrogenase deficiency or
             glucose-galactose malabsorption, etc.

          -  Male subject who don't have willing to accept medically acceptable contraceptive
             methods during the course of clinical trial, or who plan to provide sperm.

          -  A subject who is determined to be ineligible to participate in the clinical trial by
             the investigator for other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-ryul Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

